ICON has extensive experience in cardiovascular clinical research trials across the entire drug development spectrum.

Despite the advances in the cardio-metabolic field over the past 20 years, cardiovascular and metabolic diseases remain the leading causes of morbidity and mortality worldwide. The need to discover and develop better, safer and more cost-effective drugs and devices remains.

ICON, a full-service provider, takes a data-driven approach to develop strategies that will cut timelines and costs from First-in-Human (FIH) studies through post-approval. We have over 25 years of experience conducting cardiovascular trials with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.

ICON Cardiovascular experience in the last five years

  • 36,415

  • 118

  • 3,929


ICON's experienced cardio-metabolic drug and medical device development teams support clinical trials across multiple indications, including:

  • Cardiovascular


    • Atrial and Ventricular Arrhythmia
    • Cardiomyopathy (e.g., ATTR, hypertrophic, etc. with rare disease team)
    • Heart failure
    • Hypertension
    • Pulmonary Hypertension (with the respiratory team)
    • Coronary Artery Disease and Stable Angina
    • Acute Coronary syndromes, including myocardial infarction
    • Venous Thromboembolism
    • Peripheral Arterial Disease
  • Alzheimers Disease

    Atherosclerotic & embolic cerebrovascular disease

    • Stroke, TIA (with neurosciences team)
  • Mitigating the impact of COVID-19 on CV trials and participants


    • Diabetes
    • Dyslipidemia
    • Hyperuricemia

ICON services across all phases of drug and device development for your cardio-metabolic trials:

Dedicated specialist teams

ICON has a global team of in-house cardio-metabolic experts who are highly-experienced in clinical research and drug and device development. The group includes representatives from all critical functional areas and oversees trial operations in order to anticipate and proactively address potential roadblocks. We also leverage established and new relationships with renowned cardio-metabolic experts and investigators worldwide to benefit our clients.

In addition to providing support and guidance to the study team, our cardio-metabolic experts provide insight on:

  • Global project feasibility
  • Protocol development, review and evaluation
  • Clinical trial planning
  • Therapeutic training and advice
  • Project oversight
  • Consulting, medical monitoring and advisory board representation
  • Interpretation of the clinical data
  • Completion of the clinical study report


Our global investigator database includes over 5,800 cardiovascular investigative sites across more than 55 countries. As such, we have established solid working relationships with leading cardiovascular sites in all regions of the world, enabling us to provide our sponsors with efficient recruitment strategies tailored to each study.

Learn more

Cardiovascular, Metabolic and Circulation insights

ICON's Cardiovascular team contributes regularly to industry publications and media coverage of cardiovascular clinical trials. Stay up to date with ICON's latest thought leadership on cardiovascular clinical trials.

Read more